NUCANA PLC-ADR (NCNA) Fundamental Analysis & Valuation

NASDAQ:NCNA • US67022C3043

Current stock price

2.21 USD
+0.15 (+7.28%)
Last:

This NCNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NCNA Profitability Analysis

1.1 Basic Checks

  • NCNA had negative earnings in the past year.
  • NCNA had a negative operating cash flow in the past year.
  • In the past 5 years NCNA always reported negative net income.
  • NCNA had a negative operating cash flow in each of the past 5 years.
NCNA Yearly Net Income VS EBIT VS OCF VS FCFNCNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of NCNA (-98.39%) is worse than 75.15% of its industry peers.
  • The Return On Equity of NCNA (-120.66%) is worse than 60.97% of its industry peers.
Industry RankSector Rank
ROA -98.39%
ROE -120.66%
ROIC N/A
ROA(3y)-108.78%
ROA(5y)-86.72%
ROE(3y)-208.44%
ROE(5y)-154.07%
ROIC(3y)N/A
ROIC(5y)N/A
NCNA Yearly ROA, ROE, ROICNCNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • NCNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NCNA Yearly Profit, Operating, Gross MarginsNCNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

5

2. NCNA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for NCNA has been increased compared to 1 year ago.
  • NCNA has more shares outstanding than it did 5 years ago.
  • NCNA has a worse debt/assets ratio than last year.
NCNA Yearly Shares OutstandingNCNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
NCNA Yearly Total Debt VS Total AssetsNCNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 54.31 indicates that NCNA is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 54.31, NCNA belongs to the best of the industry, outperforming 95.92% of the companies in the same industry.
  • A Debt/Equity ratio of 0.03 indicates that NCNA is not too dependend on debt financing.
  • NCNA has a Debt to Equity ratio (0.03) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 54.31
ROIC/WACCN/A
WACCN/A
NCNA Yearly LT Debt VS Equity VS FCFNCNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • NCNA has a Current Ratio of 5.60. This indicates that NCNA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.60, NCNA is in line with its industry, outperforming 59.22% of the companies in the same industry.
  • A Quick Ratio of 5.60 indicates that NCNA has no problem at all paying its short term obligations.
  • With a Quick ratio value of 5.60, NCNA perfoms like the industry average, outperforming 59.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.6
NCNA Yearly Current Assets VS Current LiabilitesNCNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

1

3. NCNA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.97% over the past year.
EPS 1Y (TTM)99.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 29.76% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.62%
EPS Next 2Y28.47%
EPS Next 3Y24.37%
EPS Next 5Y29.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCNA Yearly Revenue VS EstimatesNCNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2029 2030 2031 2032 50M 100M 150M
NCNA Yearly EPS VS EstimatesNCNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1K -2K -3K

1

4. NCNA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NCNA. In the last year negative earnings were reported.
  • Also next year NCNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NCNA Price Earnings VS Forward Price EarningsNCNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NCNA Per share dataNCNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • NCNA's earnings are expected to grow with 24.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.47%
EPS Next 3Y24.37%

0

5. NCNA Dividend Analysis

5.1 Amount

  • No dividends for NCNA!.
Industry RankSector Rank
Dividend Yield 0%

NCNA Fundamentals: All Metrics, Ratios and Statistics

NUCANA PLC-ADR

NASDAQ:NCNA (4/27/2026, 5:20:02 PM)

2.21

+0.15 (+7.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18
Earnings (Next)06-01
Inst Owners4.32%
Inst Owner Change-5.6%
Ins Owners0%
Ins Owner Change0%
Market Cap843.37M
Revenue(TTM)N/A
Net Income(TTM)-29.35M
Analysts82.5
Price TargetN/A
Short Float %220.81%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 25.69
P/tB 28.25
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS0.09
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -98.39%
ROE -120.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-108.78%
ROA(5y)-86.72%
ROE(3y)-208.44%
ROE(5y)-154.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.6
Quick Ratio 5.6
Altman-Z 54.31
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)69.9%
Cap/Depr(5y)78.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
EPS Next Y83.62%
EPS Next 2Y28.47%
EPS Next 3Y24.37%
EPS Next 5Y29.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.94%
OCF growth 3YN/A
OCF growth 5YN/A

NUCANA PLC-ADR / NCNA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NUCANA PLC-ADR (NCNA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NCNA.


What is the valuation status of NUCANA PLC-ADR (NCNA) stock?

ChartMill assigns a valuation rating of 1 / 10 to NUCANA PLC-ADR (NCNA). This can be considered as Overvalued.


What is the profitability of NCNA stock?

NUCANA PLC-ADR (NCNA) has a profitability rating of 0 / 10.


What is the financial health of NUCANA PLC-ADR (NCNA) stock?

The financial health rating of NUCANA PLC-ADR (NCNA) is 5 / 10.